NZX/ASX Announcement

November 11, 2024

Springer Nature, a leading research journal, has published a report highlighting the comparable accuracy of TruScreen cervical cancer screening results to conventional Liquid-Based Cytology (LBC) in patients with different transformation zone (TZ) types. This groundbreaking study reaffirms TruScreen’s position as a simple, effective, and rapid real-time method for screening cervical cancer.

Highlights

• Evaluation of a real-time optoelectronic method for detecting cervical intraepithelial neoplasia and cervical cancer in patients with varying TZ types
• A cohort of 1,908 women aged 34.0±7.3 years who have received cytology (LBC), human papillomavirus (HPV) testing, TruScreen, and colposcopy were evaluated
• TruScreen detection accuracy was comparable to LBC, with superior performance in patients with type 3 TZ

TruScreen Group Limited is pleased to announce the publication of “Evaluation of a real-time optoelectronic method for the detection of cervical intraepithelial neoplasia and cervical cancer in patients with different transformation zone types” conducted by Dr. Fengyi Xiao and Professor Long Sui from The Cervical Diseases Centre, Obstetrics and Gynaecology Hospital of Fudan University, Shanghai, China.

The study evaluated the diagnostic value of TruScreen, a real-time diagnostic technology, for cervical lesions in patients with different TZ types. The results of this study demonstrate the accuracy and effectiveness of TruScreen in detecting cervical cancer, particularly in patients with type 3 TZ.

Full report can be downloaded from the link below:

https://www.nature.com/articles/s41598-024-78773-w

Key Findings

• TruScreen’s sensitivity was higher than LBC, with a sensitivity of 65.08% compared to 57.14%
• TruScreen’s specificity was similar to LBC, with a specificity of 64.76% compared to 64.47%

In patients with type 3 TZ, TruScreen outperformed LBC, demonstrating:

• Higher sensitivity: 72.29% vs. 65.06%
• Higher specificity: 67.39% vs. 64.29%

Martin Dillon, CEO of TruScreen Group Limited, stated: “The Fudan University study by Dr. Fengyi Xiao and Professor Long Sui affirms the TruScreen AI-enabled optoelectronic cervical cancer screening technology. As member nations of the World Health Organisation strive to eliminate cervical cancer by the end of the century, TruScreen real-time screening technology is a vital medical device to support this global task.”

TruScreen’s benefits

• Does not require expensive pathology infrastructure
• Suitable for countries with limited access to pathology laboratory testing infrastructure and qualified clinicians
• Approved and on national cervical cancer screening guidelines in China, Russia, Vietnam, and Mexico
• Currently being evaluated for inclusion into national screening guidelines in several countries

Conclusion

The publication of the Fudan University study results reaffirms TruScreen’s position as a leading cervical cancer screening technology. With its real-time diagnostic capabilities and simplicity, TruScreen is poised to support global efforts in eliminating cervical cancer.

For more information, visit www.truscreen.com or contact:

Marty Dillion
Chief Executive Officer
martindillon@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com